GlobeNewswire
-
Evaxion announces strategy and business update and third quarter 2026 financial results
19/11/2026 -
Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
19/11/2026 -
Korro to Participate in Upcoming Investor Conferences
19/11/2026 -
Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
19/11/2026 -
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
19/11/2026 -
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
19/11/2026 -
ANI Pharmaceuticals to Present at Upcoming December Investor Conference
19/11/2026 -
CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent
19/11/2026 -
EBI Reaches Key Milestone with First Patient Enrolled in Phase III EasyBoost Trial of EA-230, a Potential First-in-Class Medicine to Accelerate Recovery After Cardiac Surgery
19/11/2026 -
Zymeworks Announces Participation in Upcoming Investor Conferences
19/11/2026 -
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
19/11/2026 -
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
19/11/2026 -
A Race Against Blindness Brings Back “Miles, Magic & Mochas” Fundraiser for the Holiday Season
19/11/2026 -
Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
19/11/2026 -
ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector
19/11/2026 -
AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads
19/11/2026 -
DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
19/11/2026 -
Scancell Provides Corporate and Clinical Update
19/11/2026 -
Interim Results for the Third Quarter of 2026 - BioPorto reports continued NGAL growth and advances the U.S. Adult Validation Study
19/11/2026
Pages